AIM (AIM ImmunoTech Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by AIM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | DAVID I. CHEMEROW | Director | C | — | — |
| 2026-03-16 | Thomas K Equels | CEO & President | C | — | — |
| 2026-03-10 | DAVID I. CHEMEROW | Director | J | — | — |
| 2026-03-10 | Thomas K Equels | CEO & President | J | — | — |
| 2026-02-06 | DAVID I. CHEMEROW | Director | A | — | — |
| 2025-07-21 | TED D KELLNER | Director | — | — | — |
| 2025-06-16 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-06-13 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-04-23 | TED D KELLNER | Director | Buy | — | — |
| 2025-04-23 | WILLIAM M MITCHELL | Director | Buy | — | — |
| 2025-04-23 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-04-07 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-04-04 | Peter W Rodino III | COO, Secretary, Gen. Counsel | Buy | — | — |
| 2025-03-18 | NANCY BRYAN | Director | A | — | — |
| 2025-03-18 | DAVID I. CHEMEROW | Director | A | — | — |
| 2025-03-18 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-03-06 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-03-05 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-03-04 | NANCY BRYAN | Director | A | — | — |
| 2025-03-04 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-03-04 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-03-04 | DAVID I. CHEMEROW | Director | A | — | — |
| 2025-02-20 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-02-20 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-02-20 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-02-19 | NANCY BRYAN | Director | A | — | — |
| 2025-02-19 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-02-03 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-02-03 | NANCY BRYAN | Director | A | — | — |
| 2025-01-21 | Thomas K Equels | CEO & President | Buy | — | — |
| 2025-01-17 | NANCY BRYAN | Director | A | — | — |
| 2025-01-17 | WILLIAM M MITCHELL | Director | A | — | — |
| 2025-01-03 | STEWART APPELROUTH | Director | A | — | — |
| 2025-01-03 | NANCY BRYAN | Director | A | — | — |
| 2025-01-03 | WILLIAM M MITCHELL | Director | A | — | — |
| 2024-12-20 | WILLIAM M MITCHELL | Director | Sell | — | — |
| 2024-12-19 | Thomas K Equels | CEO & President | Buy | — | — |
| 2024-12-17 | WILLIAM M MITCHELL | Director | A | — | — |
| 2024-12-17 | STEWART APPELROUTH | Director | A | — | — |
| 2024-12-17 | NANCY BRYAN | Director | A | — | — |
| 2024-12-04 | STEWART APPELROUTH | Director | Buy | — | — |
| 2024-12-03 | WILLIAM M MITCHELL | Director | A | — | — |
| 2024-12-03 | NANCY BRYAN | Director | A | — | — |
| 2024-12-03 | STEWART APPELROUTH | Director | A | — | — |
| 2024-11-21 | STEWART APPELROUTH | Director | Buy | — | — |
| 2024-11-21 | Thomas K Equels | CEO & President | Buy | — | — |
| 2024-11-20 | Thomas K Equels | CEO & President | Buy | — | — |
| 2024-09-17 | Thomas K Equels | CEO & President | Buy | — | — |
| 2024-09-16 | Thomas K Equels | CEO & President | Buy | — | — |
| 2024-09-12 | Thomas K Equels | CEO & President | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,005,763 | — |
| — | Director | 522,435 | — |
| — | COO, Secretary, Gen. Counsel | 402,164 | — |
| — | Director | 389,118 | — |
| — | Director | 292,174 | — |
| — | CEO & President | 63,922 | — |
| — | Director | 31,882 | — |
| — | Chief Financial Officer | 22,915 | — |
| — | 10%+ Owner | 770 | — |
| — | Director | 11 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AIM quote page; the site-wide leaderboard is on the insider transactions hub.